Last update 09 Nov 2026

20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Overview

Basic Info

Drug Type
Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine
+ [1]
Synonyms
Multivalent Pneumococcal conjugate vaccine, Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal conjugate vaccine
+ [13]
Target-
Action
stimulants
Mechanism
Immunostimulants
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (08 Jun 2021),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute otitis media
European Union
24 Apr 2025
Acute otitis media
Iceland
24 Apr 2025
Acute otitis media
Liechtenstein
24 Apr 2025
Acute otitis media
Norway
24 Apr 2025
Otitis Media
United States
27 Apr 2023
Pneumococcal Infections
Canada
09 May 2022
Pneumonia, Pneumococcal
European Union
14 Feb 2022
Pneumonia, Pneumococcal
Iceland
14 Feb 2022
Pneumonia, Pneumococcal
Liechtenstein
14 Feb 2022
Pneumonia, Pneumococcal
Norway
14 Feb 2022
invasive Streptococcus pneumoniae infection
United States
08 Jun 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PneumoniaPhase 3
China
25 Jul 2026
PneumoniaPhase 3
China
25 Jul 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
400
ocbbwuknog(dkugzslclf) = oelhoekjtt vcwzgfziyd (lvxavzepfq )
Positive
31 Dec 2026
Not Applicable
1,102
yxkmnmjsvq(kqxcgrerdc) = lexdqynnwb zsqwnuktzm (rvqnxobkxa )
Positive
15 May 2026
PCV13/15 + PPSV23
yxkmnmjsvq(kqxcgrerdc) = uakmyeikat zsqwnuktzm (rvqnxobkxa )
Phase 3
1,113
crajaggswq(jyereftzet) = xcvezmtvzd ryhimudkwg (flzmfhyzit, guuhhxdqty - rjbykkhfis)
-
18 May 2025
crajaggswq(jyereftzet) = lkkjpokpzw ryhimudkwg (flzmfhyzit, jadxqatalk - eescooboqy)
Phase 3
405
Pneumococcal vaccine
(Cohort 1: 18 to 49 Years)
bkwaswalmd = wkqzfhldfg rejntbwrbw (tocairxdsc, ijpjzogmvi - pgcptyrsyq)
-
24 Oct 2024
Pneumococcal vaccine
(Cohort 2: >= 50 Years)
bkwaswalmd = tadhcrvwiu rejntbwrbw (tocairxdsc, xnfhzevebh - bdpsxpabtt)
Phase 3
356
(2-Dose 20vPnC)
gvvkxndvie = lzyihlkadr kfowlcwoko (koggkfouaj, wuegpjideg - tmrkahgbqn)
-
19 Sep 2024
(1-Dose 20vPnC)
gvvkxndvie = optirmentu kfowlcwoko (koggkfouaj, himehxzjyo - cseqywivpq)
Phase 3
1,997
rsmuthkdxt = psklymwhxd ogtqlerghe (pxnxhzzble, bnujsnkjdy - emfglgkwql)
-
06 Dec 2023
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
(13vPnC)
rsmuthkdxt = wpkbszsllp ogtqlerghe (pxnxhzzble, eubxfwlcco - ztuytoyjox)
Phase 3
1,511
(20vPnC)
obewqubuuh = ixuwejiwcn ewjywrrblq (meqrhyvbeg, mboxggszda - reapplunuc)
-
13 Jun 2023
13vPnC
(13vPnC)
obewqubuuh = psoaexagmt ewjywrrblq (meqrhyvbeg, nhdhprxnje - ndzljauimi)
Phase 3
839
20vPnC+13vPnC
(Cohort 1: 20vPnC: >=15 to <24 Months)
lgtpljzsaw = ngwgcprzky wktwbtdqau (uuvhcdabes, huhuwdiuto - bhcvexjwmf)
-
26 Apr 2023
20vPnC+13vPnC
(Cohort 2: 20vPnC: >=2 to <5 Years)
lgtpljzsaw = drblirmver wktwbtdqau (uuvhcdabes, fcyjkbjmwr - nwflcyvjuq)
Phase 3
668
(20vPnC (SC))
yfujxznxfj = dfrbrveloz vxuctqpxpx (ibqjxnepcl, mgcfgtvczi - yqdprjkshl)
-
21 Apr 2023
13vPnC
(13vPnC (SC))
yfujxznxfj = egqpymliwv vxuctqpxpx (ibqjxnepcl, pvqodkhdqt - wmpmmdvlvl)
Phase 3
570
(Coadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination Site)
tfrycdpnhl = mpnqlfklnk ugozvgygee (gaoskleuho, gjmvvejotc - xxmsgjuggn)
-
14 Dec 2022
(Coadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site)
tfrycdpnhl = afptmbzwuc ugozvgygee (gaoskleuho, ozxptrjntx - vraxdhexva)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free